

A Comprehensive Review On Cdsco: Pharmaceutical Regulatory Authority Of India.

MS. Divya Ravindra Pawar ., Mr. Atish.B.Velhal Prof. (Dr) V.K. Redasani Ms. Komal Ramesh Lohar Ms. Amruta Dipak Pawara

INSTITUTE NAME AND ADRESS : Yashoda Shikshan Prasarak Mandal, Yashoda Technical Campus, Faculty of Pharmacy(B. Pharmacy), Wadhe , Satara - 415001

Submitted: 25-05-2023 Accepted: 05-06-2023

ABSTRACT:

Manufacture, sale and regulation below the Drugs and Cosmetics Act. First, drug distribution is under the auspices of state agencies and centers. The authority is responsible for approving new drugs in country, clinical trials. Lowering pharmaceutical standards and quality control and adjustment of imported pharmaceuticals Providing specialist advice on the activities and provision of national anti-drug organisations Enforcement Unit of the "Pharmaceutical and Cosmetic Products Act". drug controller The Indian General is responsible for approving licenses for certain categories of drugs. Plasma and blood products, I.V., fluids, vaccines and serum..⁽¹⁾

KEYWORDS: CDSCO , Headquaters , Clinical trials , D & C Act , Central drug testing , DTAB - DCC.


I. INTRODUCTION:

Central Drugs Standard Control Organization (CDSCO) is the national organization of India. Regulatory Agency for Cosmetics, Drugs and Medical Devices. The Governmentof India has declared plans to take all medical devices, including implants and birth control pills, under the Central Drugs and Standard Control. organization (CDSCO)⁽²⁾

The Standard Medicines Control Organization (CDSCO) intends to provide a single point of contact system. Permits, approvals and other necessary powers. This behavior is designed to push. The Make in India initiative, part of Pharma Vision 2020, was presented at a high level Indian Govt. ⁽³⁾ (⁴⁾


CDSCO has always been committed to transparency, liability and consistency of services to ensure the safety, effectiveness and quality of medical products It is produced, imported and distributed domestically. (2)

• OrganizationStructure^{:(5)}



International Journal of Pharmaceutical Research and Applications

Volume 8, Issue 3 May-June 2023, pp: 2101-2106 www.ijprajournal.com ISSN: 2249-7781



MainBodies:-

- 1. CentralDrugStandardControlOrganization(CD SCO)
- 2. MinistryofHealth &FamilyWelfare(MHFW).
- 3. IndianCouncilofMedical Research(ICMR).
- 4. IndianPharmaceuticalAssociation(IPA).
- 5. DrugTechnicalAdvisoryBoard(DTAB).
- $6. \quad Central Drug Testing Laboratory (CDTL). \\$
- 7. IndianPharmacopoeiaCommission(IPC).
- 8. NationalPharmaceuticalPricingAuthority(NPP A). (6)

HeadquartersOFCDSCO:

The National Regulatory Authority of India (NRA) is the central pharmaceutical standard. Control Organization (CDSCO), part of the Directorate General of Health Services Ministry of Health and Family Welfare, Government of India. Its headquarters are at FDA Bhawan, Kotla Road, New Delhi 110002. The organization also has 6 regional offices, 4 sub-regional offices, 13 port offices and There are 7 research institutes in this field (7)

Volume 8, Issue 3 May-June 2023, pp: 2101-2106 www.ijprajournal.com ISSN: 2249-7781

ROLEOFCDSCO⁽⁸⁾: II. Processing &Conducting the ClinicalTrials For Approval of Licensing & NewDrug importRegistra tion RoleofCDSCO Drug&CosmeticsBa NewDrugTesting nning Market Surveillance throughinspectorate centre & State Authority

III. FUNCTIONOFCDSCO:

- The central licensing authority is responsible for:
- 1. Approval of a new drug.
- 2. Conducting clinical research.
- 3. Quality control, import registration and approval of imported drugs .
- 4. Coordinating the activities of national drug control agencies by providing professionaladvice Save the D&C A form ⁽⁹⁾
- State licensing agencies are responsible for:
- 1. Regulation of the production, sale and supply of pharmaceutical products ⁽⁹⁾
- Other features:
- 1. Blood Bank, LVP, Vaccine, Recombinant Drug Approval DNA products and certain medicaldevices.
- 2. Review of the D&C Act.
- 3. Prohibition of using outdated medicines and cosmetics.
- 4. Export Test Licence, Individual Licence, NOC (No Objection Certificate) submission.
- 5. New drug and cosmetic tests (9)

☐ Functions of Central Drug Testing Labora tories:

- 1. The role of the appeal body in disputes related to pharmaceutical quality.
- 2. Acquisition, storage and distribution of International Pharmaceutical Reference Standards these
- 3. Analyst training appointed by the National Drug Control Laboratories and other agencies .
- 4. Training of WHO staff abroad in advanced analytical methods.
- 5. The Center advises drug control agencies on the quality and toxicity of drugs.
- 6.Authorization is pending. Pharmaceutical and cosmetic research and analysis.
- 7. Analysis of the registration pattern to verify location registration according to good manufacturing practice (GMP). (9)

• CDSCO Registration Type:

CDSCO may approve registrations for several reasons:

- 1. Registration of cosmetic products .
- 2. NOC for release.
- 3. Ethical standards.



International Journal of Pharmaceutical Research and Applications

Volume 8, Issue 3 May-June 2023, pp: 2101-2106 www.ijprajournal.com ISSN: 2249-7781

- 4. Blood products and blood banks.
- 5. Formula development and research.
- 6. NOC for dual use.
- 7. BA/BE authorized site. (10). (10)

Act&RulesgovernbyCDSCO

• Pharmaceuticals and Cosmetics Act, 1940

It regulates the import, production, distribution and sale of pharmaceutical products. It is reasonable to increase the quantity, but not the quantity of pharmaceutical and cosmetic products. The law is based on a resolution from the perspective of legislators in each state. (11)

• DTAB-DCC:


This separation deals with forming and convening meetings of 'Drugs Technical AdvisoryBoard (DTAB) and 'Drugs Consultative Committee (DCC). The approvals of DTAB andDCC on the substances rose out of administration of the Drugs and Cosmetics Act and Rulesthereunder shall be completed by adjusting the applicable particulars of the Drugs and Cosmetics ActandRules thereunder.

Functionalities:

- 1. Coordination of DTAB meetings led by the Director of Health Technical Advisory Service (DGHS) to Central and State Governmentsissues arising from the implementation of the Drugs and Cosmetics Act of 1940; Other functions assigned to him by this law.
- 2. Study, collate and review comments/suggestions/counters received Newspaper announcement / announcement / circular etc.
- 3. Adjustment of the composition of the subcommittees presented at the DTAB and DCC meetingsFollow the reports.
- 4. Coordination of meetings with interested parties related to changes in medicine and cosmetics Provisions as per MOHFW recommendations where applicable. Issuing the import permit for new medicines.
- 5. Blood bank monitoring.
- 6. The right to initiate a clinical trial.
- 7. License for the marketing of new medicines.
- 8. On-site inspection of clinical trials to protect the rights and interests of subjects Checking data quality and integrity (11)

InternationalCellDivision:(1)

Organogram



IIDEA lournal

International Journal of Pharmaceutical Research and Applications

Volume 8, Issue 3 May-June 2023, pp: 2101-2106 www.ijprajournal.com ISSN: 2249-7781

- ☐ TheHumanResourcesutilizedbyCDSCOforfollow ingpurposes:
- 1.Standard quality pharmaceutical production management.
- 2.Provide work standards to production departments.
- 3. Production license.
- 4. Train production departments to take into account that drugs are not of standard quality.
- 5. Available on the market.
- 6. Publication of drug prohibitions and/or revocations in the Official Gazette.
- 7. Confirm approved dose combinations with drug dosages and indications.
- 8. License to import new drugs.
- 9. Blood bank management.
- 10. Allow the clinical trial to begin.
- 11. Marketing authorization of new medicines.
- 12. Identifying Clinical Trial Research Sites to Protect Participants' Rights Verify data quality and integrity (12)

DublicRelationOffice(PRO):

PR Office (PRO):

The Public Relations Office of CDSCO is a special agency established with a mandate. It serves as an interface between CDSCO and stakeholders, including the general public. We exchange and disseminate information for the following purposes:

- 1. One. It serves as a "one stop shop" to resolve stakeholder grievances.
- 2. Provide information to innovators on legal requirementsMarket their products.
- 3. Describe the Drug and Cosmetic Act of 1940 and its regulationsUnder the.
- 4. Guidance and support to investors at various stages of the relevant business life cycle.(11)

IV. ACKNOWLEDGEMENT:

In this project work. I have studied and learnt brief information about Drug Regulatory Affair . I would like to express my gratitude to my mentor Mr. Atish B. Velhal , B Pharm HOD Mr . A. M. Bhagwat and Hon .Principal Dr. V. K. Redasani . who gave this valuable opportunity to this informative work entitled do Comprehensive Review on **CDSCO** Pharmaceutical Regulatory Authority of India "which will help me in research work and has increased my understanding of the subject.

Secondly I would like to thank my parents and

friends (Amruta , Komal , Rhituja and Pratiksha)for helping me in finishing this project within limited time.

REFERENCES:

- [1]. PardeshiAA.RoleandFunctionofDrugRegu latoryAuthoritiesintheBackdropofGoodGo vernance. Availableat SSRN1748629.
- [2]. Central Drugs StandardControl
 Organisation (no date)
 http://cdscoonline.gov.in/CDSCO.
- [3]. DanS,BoseA,GhoshB,MandaPT.NewDrug sandClinicalTrialsRules-2018"(GSR-104E)byCDSCO:It'sImpactonBA.BEStud iesinIndia.PharmRegulAff Open Access. 2018;7(2):1000208
- [4]. ReddyS,MounicaNV,AnushaS,Evangeline L,NagabhushanamMV,Nagarjunareddy D, Bonthargala B. Regulatory Requirements of 'Similar Biologics 'forMarketing AuthorizationinIndia.

 InternationalJournalof Drug RegulatoryAffairs.2017;5(1):20-4.
- [5]. Mankar SD, Gholap VD, Zende TP, Dighe RS. Drug regulatory agencies in India,USA, Europe and Japan: A review. International Journal of Institutional Pharmacy andLifeSciences.2014;4(2):288-300
- [6]. Patel, P.V. (2018) "Drug regulation in India: SWOT analysis," International JournalofDrugRegulatoryAffairs,3(3),pp.2 1– 27.Availableat:https://doi.org/10.22270/ijd ra.v3i3.168
- [7]. Kumar,M.(nodate)
 CDSCO(CentralDrugsStandardControlOr
 ganization
- [8]. SalveMP,JadhavMV.ReviewonDrugRegul atoryAffairsandNewDrugApprovalProcess inIndia.Journalhomepage:www.ijrpr.com ISSN:;2582:7421
- [9]. Sri,S.(nodate)"AReviewonPharmaceutical RegulatoryAgenciesofIndia,USA,andEuro pe,"InternationalJournal forResearchTrends andInnovation, 5(3).
- [10]. Shukla,S.(nodate)"ImportanceofCDSCOC ertificateinPublicHealthDomain-AnOverview."
- [11]. Central Drugs Standard Control Organization (no date) Central Drugs StandardControl Organization Directorate



International Journal of Pharmaceutical Research and Applications

Volume 8, Issue 3 May-June 2023, pp: 2101-2106 www.ijprajournal.com ISSN: 2249-7781

General of Health Services Ministry of Health andFamilyWelfare Government of India.Available at:https://cdsco.gov.in/opencms/opencms/en/Home(Accessed:April25,2023)

[12]. DipakKM.FeebleRegulatoryAffairsWeake ntheBackboneofIndianDrugIndustries.